C-terminal domain of p16INK4a is adequate in inducing cell cycle arrest, growth inhibition and CDK4/6 interaction similar to the full length protein in HT-1080 fibrosarcoma cells

Journal of Cellular Biochemistry

Volumn 111, Issue 6, 2010, Pages 1598-1606

  Fahham, Najmeh ^a   Sardari, Soroush ^a   Ostad, Seyed Nasser ^b   Vaziri, Behrouz ^a   Ghahremani, Mohammad Hossein ^b  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

ankyrin repeat; cell cycle; fibrosarcoma; functional domain; p16INK4a

Indexed keywords

ANKYRIN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL GROWTH; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; FIBROSARCOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IN VITRO GENE TRANSFER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; WESTERN BLOTTING;

CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FIBROSARCOMA; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78649778734     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22892     Document Type: Article

References (40)

1. Batchelor AH, Piper DE, de la Brousse FC, McKnight SL, Wolberger C,. 1998. The structure of GABPalpha/beta: an ETS domain- ankyrin repeat heterodimer bound to DNA. Science 279: 1037-1041.
2. Baumgartner R, Fernandez-Catalan C, Winoto A, Huber R, Engh RA, Holak TA,. 1998. Structure of human cyclin-dependent kinase inhibitor p19INK4d: comparison to known ankyrin-repeat-containing structures and implications for the dysfunction of tumor suppressor p16INK4a. Structure 6: 1279-1290.
3. Byeon IJ, Li J, Ericson K, Selby TL, Tevelev A, Kim HJ, O'Maille P, Tsai MD,. 1998. Tumor suppressor p16INK4A: determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4. Mol Cell 1: 421-431.
4. Classon M, Harlow E,. 2002. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2: 910-917.
5. Fahham N, Ghahremani MH, Sardari S, Vaziri B, Ostad SN,. 2009. Simulation of different truncated p16 forms and in silico study of interaction with Cdk4. Cancer Inform 7: 1-11.
6. Fahraeus R, Lane DP,. 1999. The p16(INK4a) tumour suppressor protein inhibits alphavbeta3 integrin-mediated cell spreading on vitronectin by blocking PKC-dependent localization of alphavbeta3 to focal contacts. Embo J 18: 2106-2118.
7. Fahraeus R, Paramio JM, Ball KL, Lain S, Lane DP,. 1996. Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A. Curr Biol 6: 84-91.
8. Frost SJ, Simpson DJ, Clayton RN, Farrell WE,. 1999. Transfection of an inducible p16/CDKN2A construct mediates reversible growth inhibition and G1 arrest in the AtT20 pituitary tumor cell line. Mol Endocrinol 13: 1801-1810.
9. Harada H, Nakagawa K, Iwata S, Saito M, Kumon Y, Sakaki S, Sato K, Hamada K,. 1999. Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer Res 59: 3783-3789.
10. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB,. 1995. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55: 4525-4530.
11. Koh J, Enders GH, Dynlacht BD, Harlow E,. 1995. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375: 506-510.
12. Li J, Byeon IJ, Ericson K, Poi MJ, O'Maille P, Selby T, Tsai MD,. 1999. Tumor suppressor INK4: determination of the solution structure of p18INK4C and demonstration of the functional significance of loops in p18INK4C and p16INK4A. Biochemistry 38: 2930-2940.
13. Li W, Fan J, Hochhauser D, Banerjee D, Zielinski Z, Almasan A, Yin Y, Kelly R, Wahl GM, Bertino JR,. 1995. Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proc Natl Acad Sci U S A 92: 10436-10440.
14. McConnell BB, Gregory FJ, Stott FJ, Hara E, Peters G,. 1999. Induced expression of p16(INK4a) inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes. Mol Cell Biol 19: 1981-1989.
15. McDonald NQ, Peters G,. 1998. Ankyrin for clues about the function of p16INK4a. Nat Struct Biol 5: 85-88.
16. Michaely P, Bennett V,. 1993. The membrane-binding domain of ankyrin contains four independently folded subdomains, each comprised of six ankyrin repeats. J Biol Chem 268: 22703-22709.
17. Obexer P, Hagenbuchner J, Rupp M, Salvador C, Holzner M, Deutsch M, Porto V, Kofler R, Unterkircher T, Ausserlechner MJ,. 2009. p16INK4A sensitizes human leukemia cells to FAS- and glucocorticoid-induced apoptosis via induction of BBC3/Puma and repression of MCL1 and BCL2. J Biol Chem 284: 30933-30940.
18. Ortega S, Malumbres M, Barbacid M,. 2002. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 1602: 73-87.
19. Paggi MG, Baldi A, Bonetto F, Giordano A,. 1996. Retinoblastoma protein family in cell cycle and cancer: a review. J Cell Biochem 62: 418-430. (Pubitemid 26301541)
20. Parry D, Peters G,. 1996. Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma. Mol Cell Biol 16: 3844-3852.
21. Pavletich NP,. 1999. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol 287: 821-828.
22. Plath T, Detjen K, Welzel M, von Marschall Z, Murphy D, Schirner M, Wiedenmann B, Rosewicz S,. 2000. A novel function for the tumor suppressor p16(INK4a): induction of anoikis via upregulation of the alpha(5)beta(1) fibronectin receptor. J Cell Biol 150: 1467-1478.
23. Ramirez PT, Gershenson DM, Tortolero-Luna G, Ramondetta LM, Fightmaster D, Wharton JT, Wolf JK,. 2001. Expression of cell-cycle mediators in ovarian cancer cells after transfection with p16(INK4a), p21(WAF1/Cip-1), and p53. Gynecol Oncol 83: 543-548.
24. Roninson IB,. 2003. Tumor cell senescence in cancer treatment. Cancer Res 63: 2705-2715.
25. Russo AA, Tong L, Lee JO, Jeffrey PD, Pavletich NP,. 1998. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature 395: 237-243.
26. Serrano M,. 1997. The tumor suppressor protein p16INK4a. Exp Cell Res 237: 7-13.
27. Smith-Sorensen B, Hovig E,. 1996. CDKN2A (p16INK4A) somatic and germline mutations. Hum Mutat 7: 294-303.
28. Tang KS, Fersht AR, Itzhaki LS,. 2003. Sequential unfolding of ankyrin repeats in tumor suppressor p16. Structure 11: 67-73.
29. Tang KS, Guralnick BJ, Wang WK, Fersht AR, Itzhaki LS,. 1999. Stability and folding of the tumour suppressor protein p16. J Mol Biol 285: 1869-1886.
30. Tevelev A, Byeon IJ, Selby T, Ericson K, Kim HJ, Kraynov V, Tsai MD,. 1996. Tumor suppressor p16INK4A: structural characterization of wild-type and mutant proteins by NMR and circular dichroism. Biochemistry 35: 9475-9487. (Pubitemid 26320054)
31. Villacanas O, Perez JJ, Rubio-Martinez J,. 2002. Structural analysis of the inhibition of Cdk4 and Cdk6 by p16(INK4a) through molecular dynamics simulations. J Biomol Struct Dyn 20: 347-358.
32. Weinberg RA,. 1995. The retinoblastoma protein and cell cycle control. Cell 81: 323-330.
33. Whitaker NJ, Bryan TM, Bonnefin P, Chang AC, Musgrove EA, Braithwaite AW, Reddel RR,. 1995. Involvement of RB-1, p53, p16INK4 and telomerase in immortalisation of human cells. Oncogene 11: 971-976.
34. Xie QC, Hu YD, Wang LL, Chen ZT, Diao XW, Wang ZX, Guan HJ, Zhu B, Sun JG, Duan YZ, Chen FL, Nian WQ,. 2005. The co-transfection of p16(INK4a) and p14(ARF) genes into human lung cancer cell line A549 and the effects on cell growth and chemosensitivity. Colloids Surf B Biointerfaces 46: 188-196.
35. Yang R, Gombart AF, Serrano M, Koeffler HP,. 1995. Mutational effects on the p16INK4a tumor suppressor protein. Cancer Res 55: 2503-2506.
36. Yang R, Serrano M, Slater J, Leung E, Koeffler HP,. 1996. Analysis of p16INK4a and its interaction with CDK4. Biochem Biophys Res Commun 218: 254-259.
37. Yarbrough WG, Buckmire RA, Bessho M, Liu ET,. 1999. Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors. J Natl Cancer Inst 91: 1569-1574.
38. Yuan C, Li J, Selby TL, Byeon IJ, Tsai MD,. 1999. Tumor suppressor INK4: comparisons of conformational properties between p16(INK4A) and p18(INK4C). J Mol Biol 294: 201-211.
39. Zhang B, Peng Z,. 2000. A minimum folding unit in the ankyrin repeat protein p16(INK4). J Mol Biol 299: 1121-1132.
40. Zhang B, Peng ZY,. 2002. Structural consequences of tumor-derived mutations in p16INK4a probed by limited proteolysis. Biochemistry 41: 6293-6302.